NCT00183391View on ClinicalTrials.gov

Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children

PHASE4CompletedINTERVENTIONAL
Enrollment

232

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
DRUG

Atomoxetine

Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.

DRUG

Methylphenidate

Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.

Trial Locations (2)

10029

Icahn School of Medicine at Mount Sinai, New York

60612

University of Illinois, Chicago - Institute for Juvenile Research, Chicago

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT00183391 - Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children | Biotech Hunter | Biotech Hunter